CompletedPhase 2

A Study of ZT002 Injection With Subjects With Overweight or Obesity

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of ZT002 Injection in Subjects With Overweight or Obesity

Lead sponsor

Beijing QL Biopharmaceutical Co.,Ltd

Asset

Zovaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

303

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥28

Primary endpoint

•Weight after 24 weeks of treatment

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07020884

Org study IDBJQL-ZT002-2001

Timeline

Milestones

Study start2024-08-14actual

Primary completion2025-05-07actual

Study completion2025-05-29actual

Study first posted2025-06-13actual

Last update posted2025-12-10actual

Assets

Investigational agents

Zovaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age ≥ 18 years and ≤ 75 years.

•BMI ≥28 kg/m², or 24 kg/m2 ≤ BMI < 28 kg/m2 with at least one comorbidity (pre-diabetes, hypertension, hyperlipidemia, fatty liver, obstructive sleep apnoea syndrome due to overweight, weight-bearing joint pain, etc.)

•Weight change is not more than 5% with diet and exercise control alone within 3 months prior to screening.

Exclusion criteria

•Previous diagnosis of diabetes; or HbA1c ≥ 6. 5% or fasting blood glucose ≥ 7.0 mmol/L at screening.

•Have used medicines or treatments that affect weight within 3 months prior to screening.

•History of acute or chronic pancreatitis.

•Personal or family (parents, children, and siblings) history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type II (MEN2).

•History of definite mental disease within 2 years prior to screening or prior suicidal tendency or suicidal behavir; or PHQ-9 scale score is ≥ 15 at screening; or C-SSRS questionnaire is either class 4 or 5 at screening.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

2 endpoints

Primary/protocol endpoint

The percentage change from baseline in weight after 24 weeks of treatment.

Time frame:baseline, 24 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

The proportion of subjects with weight loss of ≥ 5%, ≥ 10%, and ≥ 15% from baseline after 24 weeks of treatment;

Time frame:24 weeks

threshold achievement, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.